Citoxlab Group, a leading non-clinical CRO, entered into a definitive agreement to acquire Solvo Biotechnology, a CRO specializing in drug transporter studies and the assessment of Drug-Drug Interactions (DDI).
Solvo Biotechnology is the international leader in the field of drug transporter research. This field is growing rapidly as the investigation of the transport mechanisms becomes pivotal for drug development. Transporter studies are a regulatory requirement for entering large clinical trials and then requesting a marketing authorization from health regulatory agencies. Solvo Biotechnology has a staff of around 100 people, located on two sites in Budapest and Szeged, Hungary.
Through this new acquisition Citoxlab reinforces its leading position in the non-clinical CRO field, with consolidated sales of €136 million and a staff of 1,300, spread over nine sites – France (Evreux and Saint-Nazaire), Canada (Laval and Boisbriand), the US (Kansas-City), Denmark (Copenhagen) and Hungary (Veszprém, and now Budapest and Szeged).
Citoxlab Group offers a comprehensive range of preclinical services to meet the needs of pharmaceutical, biotechnology, medical device, chemical and agrochemical companies worldwide. Citoxlab carries out studies in general and reproductive toxicology, carcinogenicity, immunology, pharmacology, pharmacokinetics and bioanalysis/biomarkers.